The core of the litigation centers on claims that PROCEPT BioRobotics utilized an aggressive discount program to inflate reported U.S. handpiece sales. According to the complaint, the company incentivized bulk orders that far exceeded actual procedure demand, effectively pulling future revenue into the present. This practice allegedly resulted in a surplus of more than 10,000 excess units sitting in field inventory by the end of the class period.

Plaintiffs argue that these actions obscured the company’s true financial health and misled shareholders about the actual utilization of its medical systems. By failing to disclose the extent of this overstocking, the company allegedly painted an unsustainable picture of its operational success. Investors seeking to participate in the action or clarify their legal standing can contact the Law Offices of Frank R. Cruz at 310-914-5007 or via their official website.